Distinct Profile Differences in Subjective Cognitive Decline in the General Public Are Associated with Metacognition, Negative Affective Symptoms, Neuroticism, Stress, and Poor Quality of Life by Amy, Jenkins et al.




Distinct Profile Differences in Subjective
Cognitive Decline in the General Public Are
Associated with Metacognition, Negative
Affective Symptoms, Neuroticism, Stress,
and Poor Quality of Life
Amy Jenkinsa,∗, Jeremy Treeb and Andrea Talesa
aCentre for Innovative Ageing, Swansea University, Wales, UK
bDepartment of Psychology, Swansea University, Wales, UK
Accepted 22 January 2021
Pre-press 23 February 2021
Abstract.
Background: Subjective cognitive decline (SCD) is increasingly recognized in both the clinical and research arenas as a
risk factor for mild cognitive impairment (MCI) and dementia. Although SCD is etiologically heterogeneous and potentially
treatable, in comparison to MCI and Alzheimer’s disease, SCD remains poorly characterized with its clinical relevance often
questioned.
Objective: This study’s aim was to improve the characterization of SCD within the general public.
Methods: Individuals with SCD were compared to those without via a battery of measures.
Results: Both the SCD and the non-SCD group correlational analysis identified significant relationships between worse
SCD, worse metacognitive dysfunction, negative affective symptoms, and greater levels of stress. The SCD group displayed
additional correlational relationships between Cognitive Change Index (Self report) (CCI-S) scores, higher neuroticism
scores, and poorer quality of life (QoL). Partial correlation analysis in the SCD group suggests CCI-S scores, anxiety,
depression, and metacognition are intercorrelated. Ad hoc analyses using metacognition as the grouping variable found that
those experiencing worse metacognitive dysfunction were significantly more likely to experience poorer SCD, psychological
and social QoL, greater levels of anxiety, depression, stress, and neuroticism.
Conclusion: The emerging pattern from the analysis indicates that SCD appears associated with sub-clinical negative affective
difficulties, metacognitive, and other psycho-social issues, and poorer QoL. Dysfunctional cognitive control at a meta-level
may impact someone’s ability to rationally identify cognitive changes, increase worry about cognitive changes, and allow such
changes to impact their lives more than those with superior metacognitive control. Findings could impact SCD assessment,
monitoring, early intervention, and ultimately reducing risk of further decline.
Keywords: Alzheimer’s disease, anxiety, dementia, depression, metacognition, neuroticism, quality of life, stress, subjective
cognitive decline
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INTRODUCTION
Subjective cognitive decline (SCD) is evident prior
to the onset of clinical impairment, is based on self-
reporting, and could function as a specified group for
trials on early intervention [1]. SCD is increasingly
recognized in both the clinical and research arena as
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a risk factor for mild cognitive impairment (MCI)
and dementia, particularly Alzheimer’s disease (AD)
[2]. However, compared to MCI and AD, SCD re-
mains relatively poorly characterized and appears
etiologically heterogeneous, with debate continuing
regarding its clinical relevance and importance in
relation to dementia.
Various terms have been introduced prior to SCD,
namely subjective cognitive impairment; subjective
memory complaints; subjective cognitive complai-
nts; subjective memory impairment. They are often
used interchangeably resulting in a lack of specifi-
city, confusion, and heterogeneity [2]. For this res-
earch, the term SCD will be used for cognitively
unimpaired subjects experiencing subjective cogni-
tive changes relative to previous performance levels.
Jessen et al. (2014) suggested this more appropriate
term to reflect the neurodegenerative decline associ-
ated with AD [2]. Thus, they created a specific term
and common concept to facilitate research, enable
comparability, and synergy throughout the research
literature. Due to subjective complaints being etiolog-
ically heterogeneous and unspecific, the Subjective
Cognitive Decline Initiative (SCD-I) was created to
help develop a common research framework for char-
acterizing SCD, thus subjective complains due to
pre-clinical AD [2]. SCD-I highlighted specific vari-
ables which should be considered SCD plus variables.
Hence, variables that indicate an increased risk of
developing AD such as a subjective decline in mem-
ory, rather than other domains of cognition, age at
onset of SCD ≥ 60 years, onset of SCD within the
last 5 years, confirmation of cognitive decline by
an informant, and concerns/worries associated with
SCD [2].
SCD may, for some individuals, represent individ-
ual differences of the normal aging process. What is
in fact normal aging for a particular individual expe-
riencing symptoms of SCD can often be considered
as ‘senior moments’ [3], thus moments considered to
be not of serious consequences and often regarded
humorous. Past research has suggested that SCD
can also be due to reversible causes such as anxi-
ety and depression [4, 5], thus potentially modifiable
risk factors [6]. Consequently, treating the poten-
tially reversible causes of SCD could result in the
removal or reduction in severity of SCD symptoms
and improve healthy aging, and in some instances,
reduce overall risk of developing dementia in the
long term [2, 6, 7]. Therefore, the factors contributing
to SCD may be more heterogeneous and multi-
faceted than previously and commonly envisaged, for
instance, negative affective symptoms. Furthermore,
irrespective of etiology, SCD can be detrimental to
quality of life (QoL), self-perceived health [8, 9],
and self-perceived workplace performance [7], and
could contribute to restrictions in mobility and social
activities [10, 11].
Further research is required to identify SCD cau-
sality, characteristics, consequences, and possible
treatments [10]. It is imperative to identify whether
such factors could provide clarity on potentially
reversible causes or neurodegenerative etiology.
Subjective cognitive decline, negative affective
symptoms, stress, neuroticism, metacognition,
and poor quality of life
Although debate continues with respect to cause
and effect, increasing evidence is indicative of links
between SCD and negative affective symptoms (anxi-
ety and depression), lower self-efficacy, the reporting
of health troubles, less perceived control of life’s
difficulties, and poorer QoL [8, 9, 12–19]. Less
often investigated is the relationship between SCD,
neuroticism, metacognition, and levels of stress. To
address this lack of knowledge, these factors will be
further investigated in this study. Furthermore, fac-
tors such as affective disturbances, chronic stress,
sleep disturbances, could also be the cause, contribu-
tory factors or consequence of cognitive impairment;
however, they could also lead, in turn, to further
and even accelerated cognitive decline [18, 20]. It
is imperative to identify if low mood/depression is
associated with experiences of SCD [21]. Further-
more, Millan et al. (2012) found that QoL, work, and
social functioning were severely compromised when
cognitive deficits were poorly controlled in those who
were experiencing depression at the time, and those
who were in remission [22].
Negative affective symptoms
The most commonly identified concurrent con-
ditions in older adults have been found to be dep-
ression and cognitive impairment [5]. Dementia risk
increases when adverse factors such as depression,
anxiety, and stress are present [23]. Donovan et al.
(2014) identified that affective symptoms such as dep-
ression and anxiety are possible predictors of progres-
sion to further cognitive decline such as MCI [24].
Furthermore, approximately a third of worldwide
dementia cases may be due to possible modifiable risk
factors [6]. While the relationship between SCD with
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depression is well supported [25, 26], the causality of
depressive symptoms in SCD is difficult to determine
[10].
Several studies have also proposed that SCD is
associated with anxiety [13]. Luck et al. (2014)
identified that SCD, specifically worrisome SCD, is
predictive of neurodegenerative decline to demen-
tia [4]. Jessen et al. (2014) also proposed that the
relationship between SCD (defined by memory per-
formance on delayed verbal recall) and AD risk was
dependent on whether or not the individuals with
SCD were reporting concern about it [27]. Thus,
SCD was not predictive of AD in those individuals
who were not concerned about it suggesting it corre-
sponded more to age-associated decline rather than
AD [27]. Therefore, those who were concerned were
more likely to be experiencing memory impairment
which may be different from normal aging. These
findings support a previous study focused on mem-
ory which compared to individuals with SCD no
concerns, those with SCD concerns were at double
the risk of developing AD [28]. Evidently, there is
a relationship between negative affective symptoms
and SCD and therefore negative affective symptoms
should not be ignored in the assessment and explo-
ration of cognition. Thus, research studies should
code for depression and anxiety but not include them
in study exclusion criteria [2].
Stress, neuroticism, and metacognition
Elfgren and colleagues (2010) investigated the
impact of psychosocial stress on participants with
SCD (specifically memory decline), MCI and demen-
tia [29]. They found that psychosocial stress (i.e.,
stress relating to psychological factors and surro-
unding social environment) was significantly more
prevalent in the SCD group (71% of cases) than the
MCI group (18%) and dementia group (0%). They
proposed that psychosocial stress interferes with the
participants’ evaluation of SCD and may in fact dis-
turb the memory processes. However, at a three-year
follow-up they found that in the SCD group only 14%
reported the presence of psychosocial stress com-
pared to 71% at baseline therefore highlighting the
changeable nature of stress and the impact it can have.
Often cited in previous research is the relationship
between objectively identifiable cognitive impair-
ment (i.e., MCI and/or AD) and the personality
trait neuroticism. Evidence suggests that it mediates
the relationship between SCD (specifically memory
decline) and psychological and physical health prob-
lems [14]. Furthermore, Hill et al. (2019) identified
that neuroticism was positively related to SCD, thus
those with SCD were more likely to be neurotic com-
pared to those without [30].
The self-perception of cognitive functioning, spe-
cifically SCD, could be explained by drawing on the
idea of metacognition, thus individual’s knowledge,
understanding, and beliefs of their own cognitive
functioning [31]. Shimamura (2000) postulates that
metacognition is the control and evaluation of cogni-
tive functioning [32]. It can be argued that SCD can
be considered a form of metacognitive monitoring.
Wells (2011) proposes that metacognition relates to
beliefs about thinking, or having knowledge of cog-
nitions, with metacognitive thinking likened to an
orchestra. To produce an overture there must be a mu-
sic score and a conductor. Metacognition is the sco-
re and the conductor behind the thinking [33]. Youn
et al (2019) found that older adults with SCD, dis-
played improved cognition and identified brain region
changes as a result of a Meta Memory Training pr-
ogram (MMT). The positive impact on the brain reg-
ions is believed to relate to metacognition, thus they
suggest the MMT had an impact on improving cog-
nitive control [34]. Note, the present study measures
metacognitive beliefs, monitoring, and judgements,
not how accurate the participants are at assessing their
own cognitive ability.
Study aims
The aim of the current study was to further char-
acterize SCD in the general public with respect to
general objectively measured cognitive functioning,
anxiety, depression, QoL, stress, metacognition, and
neuroticism. We hypothesized that in comparison to
those without SCD, those with SCD will display wo-
rse metacognitive dysfunction, worse negative affec-
tive symptoms, worse levels of stress, and worse QoL,
and will be more neurotic.
METHODS
Participants
An opportunity sample methodological approach
was used. Males (N = 29) and females (N = 90) aged
55–70 years were recruited from the general public
living in South Wales, UK (Number of participants
[N] = 119; mean [M] age = 62.46 years, standard
deviation [SD] = 3.65). The inclusion criteria are, the
general public, in good to excellent general medical
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and mental health from a self-reported perspective,
thus a Likert scale response to simple questions. The
exclusion criteria are, those with a clinical diagnosis
of MCI or dementia (self-report medical diagno-
sis), self-report of decline in cognitive ability which
can be explained by a psychiatric or neurological
disease, previous head injury, medical disorder, med-
ication (prescribed and non-prescribed) known to
the participant to influence cognition, or substance
use. Participants were recruited via advertisement
on social media, group email (i.e., 50 + Network),
posters etc. This study was approved by Swansea
University ethics review boards and written informed
consent was obtained from all participants.
Battery of measures
Mean education level, ethnicity and family history
are presented in Table 1. The test battery comprised:
Cognitive Change Index (Self report) (CCI-S) to
measure SCD symptoms [35], higher score reflects
worse SCD; The World Health Organization Quality
of Life (WHOQOL-BREF; 26 items, the shortened
version of the WHOQOL-100) [36], higher score
reflects better QoL; Hospital Anxiety and Depres-
sion Scale (HADS; 14 items, 7 for anxiety and 7 for
depression) [37], higher score reflects poorer anxi-
ety and/or depression; The Big Five Inventory (BFI;
44 item scale) to measure neuroticism [38], higher
score reflects an individual being more neurotic;
Montreal Cognitive Assessment (MoCA; 30 items)
[39], higher score reflects better cognitive functi-
oning; The National Adult Reading Test (NART; 50
irregular words) to measure predicted IQ [40], hig-
her score reflects higher predicted IQ; The Meta-
Cognitions Questionnaire 30 (MCQ-30; 30 items)
to measure metacognitive beliefs, monitoring ten-
dencies, and judgement [41], higher score reflects
greater metacognitive dysfunction; The Perceived
Stress Scale (PSS; 10 items) [42], higher score ref-
lects poorer perceived stress levels.
The sample was split based on their CCI-S test
scores into the SCD group and the non-SCD group to
determine any between-group differences or within-
group relationships. The CCI-S measure has one set
of validated cut-off values to use as a method of gro-
uping, which are the ones used within the well-
established Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) study [43]. These cut-offs are based
on the first 12 CCI-S items (out of 20) which relate to
perceived memory concerns. Therefore, individuals
are believed to be experiencing memory concerns if
they score 20 or above on the first 12 items of the
CCI-S. Figure 1A and 1B show the distribution of
scores on the CCI-S measure across both the SCD
and non-SCD group.
Statistical analysis
Overall, based on Kolmogorov-Smirnov analysis
the data (i.e., on the CCI-S, MoCA, WHOQOL-
BREF, HADS, PSS, MCQ-30, and the BFI) were not
normally distributed despite score transformations,
therefore non-parametric analysis was applied (see
Supplementary Table 1). To determine differences
between the SCD and non-SCD group, the Mann-
Whitney test was employed for continuous data and
the Chi Square test was employed for categorical data.
Furthermore, correlations, thus within-group rela-
tionships, between CCI-S scores with all test battery
scores (and partial correlations) were analyzed using
non-parametric Spearman’s correlation coefficient.
Hypothesized a priori predictions were made and
therefore one-tailed analyses were run and reported
below on variables previously investigated [12], and
two-tailed analyses for those that have not.
RESULTS
As can be seen in Table 1, no significant partici-
pant characteristic group differences were identified
in age, gender, years in full-time education, ethnic-
ity, family history in cognitive impairment, general
health, predicted IQ via NART scores, and general
cognitive functioning via MoCA scores. Significant
group differences were identified in participants CCI-
S scores, thus the scores used to divide the groups
[31].
Subjective cognitive decline, general cognitive
functioning, depression, anxiety, QoL,
neuroticism, metacognition, and stress
Between-group differences
There were no significant group differences in per-
formance on general cognitive functioning, physical
health QoL, and social relationship QoL sub-scales
(all p values > 0.05) between the SCD and non-SCD
groups (Table 2). The p value for physical health QoL
was p = 0.052 and therefore only slightly below the
cut-off for significance. However, there were signifi-
cant differences between these two groups regarding
psychological and environmental QOL. There were









Participant characteristics in both the SCD and the non-SCD group
SCD Non-SCD Pearson Chi Square Test: Mann-Whitney Test:
corresponding categories in corresponding categories
the SCD & non-SCD group in the SCD & non-SCD group
Total N 44 75 – –
Age mean (SD) [y] 62.16 (3.68) 62.64 (3.65) – NS U = 1497.0 (Z = –0.846), p = 0.398
Gender N (%) 34 (77.3) Female 56 (74.7) Female NS χ2 (1, N = 119) = 0.102, p = 0.749 –
10 (22.7) Male 19 (25.3) Male
Years in FT 15.16 (2.84) 15.03 (2.62) – NS U = 1621.5 (Z = –0.159), p = 0.874
Education mean (SD)
Ethnicity group N (%) Welsh – 27 (61.4) Welsh – 48 (64) NS χ2 (2, N = 119) = 0.129, p = 0.938 –
English – 7 (15.9) English – 12 (16)
British/other – 10 (22.7) British/other – 15 (20)
Family history Yes (maternal) – 17 (38.6) Yes (maternal) – 31 (41.3) NS χ2 (2, N = 119) = 1.186, p = 0.553 –
of cognitive Yes (paternal) – 2 (4.5) Yes (paternal) – 1 (1.3)
impairment N (%) None – 25 (56.8) None – 43 (57.3)
CCI-S full scale 36.23 (7.39) 23.84 (3.19) – U = 67.50 (Z = –8.739), p < 0.001)
mean (SD) Cohen’s effect size: –0.80 Large
General health (%) Excellent – Good = 38 (86.4) Excellent – Good = 69 (92) NS χ2 (1, N = 119) = 0.972, p = 0.324 –
Fair – Poor = 6 (13.6) Fair – Poor = 6 (8)
NART errors 8.11 (5.63) 7.85 (5.40) – NS U = 1603.0 (Z = –0.260), p = 0.795
mean (SD)
MoCA mean (SD) 28.41 (1.28) 28.29 (1.26) NS U = 1563.0 (Z = –0.493), p = 0.622
NS, not significant
1236 A. Jenkins et al. / Characterising SCD
A. B.
Fig. 1A. Distribution of CCI-S scores within the non-SCD group. B. Distribution of CCI-S scores within the SCD group.
Table 2
Between-group differences
SCD Non-SCD Statistics: Mann-
Mean (SD) Mean (SD) Whitney U test
MoCA 28.41 (1.28) 28.29 (1.26) U = 1563.0 (Z = –0.493), p = 0.622
Physical Health QoL 15.93 (2.95) 16.76 (2.75) U = 1302.5 (Z = –1.943), p = 0.052
(WHOQOL-BREF)
Social relationships QoL 15.05 (3.21) 15.59 (3.28) U = 1453.5 (Z = –1.093), p = 0.274
(WHOQOL-BREF)
Psychological QoL 14.77 (2.54) 16.01 (2.42) U = 1119.5 (Z = –2.955), p = 0.003
(WHOQOL-BREF) Cohen’s effect size: –0.27 small
Environmental QoL 17.43 (1.68) 18.15 (2.96) U = 1226.5 (Z = –2.377), p = 0.017
(WHOQOL-BREF) Cohen’s effect size: –0.22 small
Anxiety (HADS) 5.86 (3.00) 3.80 (2.71) U = 956.0 (Z = –3.843), p < 0.001;
Cohen’s effect size: –0.35 medium
Depression (HADS) 3.52 (2.98) 2.28 (2.56) U = 1185.0 (Z = –2.603), p = 0.009;
Cohen’s effect size: –0.24 small
Neuroticism (BFI) 20.70 (6.36) 18.19 (5.74) U = 1264.5 (Z = –2.126), p = 0.034;
Cohen’s effect size: –0.19 small
Stress (PSS) 15.11 (7.99) 8.96 (5.44) U = 850.50 (Z = –4.408), p < 0.001;
Cohen’s effect size: –0.40 medium
Metacognition (MCQ-30) 49.77 (8.78) 43.37 (7.49) U = 959.0 (Z = –3.807), p < 0.001;
Cohen’s effect size: –0.35 medium
neuroticism, stress, and metacognition (Table 2).
Overall, the SCD group demonstrated significantly
poorer perceived psychological and environmental
QoL, greater levels of anxiety and depression, neu-
roticism, stress, and poorer scores on metacognitive
dysfunction compared to the non-SCD group.
Within-group relationships
In the non-SCD group, there were no signifi-
cant within-group correlations between CCI-S scores
and general cognitive functioning, neuroticism, and
QoL. However, there were significant positive within-
group correlations between CCI-S scores and anxiety,
depression, stress, and metacognition (Table 3). In
the SCD group, there were no significant within-
group correlations between CCI-S scores and general
cognitive functioning, and environmental QoL. How-
ever, there were significant positive within-group
correlations between CCI-S scores and neuroticism,
anxiety, depression, stress, and metacognition, and
significant negative within-group correlations with
A. Jenkins et al. / Characterising SCD 1237
Table 3
Within-group correlations between CCI-S sores and all variables: Spearman’s correlation coefficient
Non-SCD SCD
MoCA rs = –0.44, p (1-tailed) = 0.355 rs = –0.19, p (1-tailed) = 0.114
Physical Health QoL (WHOQOL-BREF) rs = –0.17, p (1-tailed) = 0.15 rs = –0.40, p (1-tailed) = 0.004
Social Relationships QoL (WHOQOL-BREF) rs = –0.00, p (1-tailed) = 0.98 rs = –0.26, p (1-tailed) = 0.046
Psychological QoL (WHOQOL-BREF) rs = –0.09, p (1-tailed) = 0.43 rs = –0.48, p (1-tailed) < 0.001
Environmental QoL (WHOQOL-BREF) rs = –0.13, p (1-tailed) = 0.27 rs = –0.16, p (1-tailed) = 0.149
Anxiety (HADS) rs = 0.28, p (1-tailed) = 0.007 rs = 0.27, p (1-tailed) = 0.037
Depression (HADS) rs = 0.34, p (1-tailed) = 0.002 rs = 0.39, p (1-tailed) = 0.005
Neuroticism (BFI) rs = 0.11, p (1-tailed) = 0.173 rs = 0.38, p (1-tailed) = 0.006
Stress (PSS) rs = 0.24, p (2-tailed) = 0.039 rs = 0.30, p (2-tailed) = 0.051
Metacognition (MCQ-30) rs = 0.27, p (2-tailed) = 0.021 rs = 0.30, p (2-tailed) = 0.045
physical QoL, psychological QoL, and social QoL,
(Table 3).
Due to the multiple comparisons being investigated
in some of the correlational analyses, the Bonferroni
correction method was used to control for the possi-
bility of type one errors. After Bonferroni correction
on the QoL sub-scales ( level 0.05/4 = 0.012), the
only significant within-group correlations to remain
were in relation to psychological (p < 0.001) and
physical (p = 0.004) QoL, not Social QoL (p =
0.046).
To identify possible unique variance between two
of the variables in the SCD group, a third variable of
interest would need to be controlled for by conduct-
ing a partial correlation. As a result of past research
indicating a clear link between anxiety, depression,
and metacognition (e.g., [31]), the relationship
between these variables and SCD were investigated.
In the SCD group, there was no association between
subjects CCI-S scores and metacognition while con-
trolling for anxiety (r (41) = 0.259, p = 0.093), depres-
sion (r (41) = 0.252, p = 0.103), or neuroticism (r
(41) = 0.224, p = 0.149). However, when controlling
for metacognition, there was an association between
subjects CCI-S scores and depression (r (41) = 0.352,
p = 0.021), and between CCI-S scores and neuroti-
cism (r (41) = 0.317, p = 0.038), but no association
between CCI-S scores and anxiety (r (41) = 0.220,
p = 0.156). The partial correlation analyses were re-
run to control for age, years in education, and gender
in addition to anxiety, depression, and neuroticism.
No association was still found between subjects CCI-
S scores and metacognition while controlling for anx-
iety (r (38) = 0.185, p = 0.254), depression (r(38) =
0.242, p = 0.132), and neuroticism (r (38) = 0.206,
p = 0.202). When controlling for metacognition, age,
years in education, and gender, there was still an
association between CCI-S scores and depression
Table 4
Metacognition as a grouping variable, between-group differences
Metacognition Metacognition Mann-Whitney:
high (N = 20) low (N = 20) between-group
(Mean and SD) (Mean and SD) differences
MoCA 27.90 (1.25) 28.70 (1.13) NS (U = 131.50 (Z = –1.913), p = 0.056)
Physical Health QoL 16.50 (2.59) 17.75 (1.59) NS (U = 146.50 (Z = –1.481), p = 0.139)
(WHOQOL-BREF)
Social Relationships QoL 14.25 (3.61) 16.85 (2.51) U = 117.50 (Z = –2.258), p = 0.024;
(WHOQOL-BREF) (Cohen’s effect size: –0.36 medium)
Psychological QoL 14.20 (2.73) 16.95 (1.76) U = 76.50 (Z = –3.384), p < 0.001;
(WHOQOL-BREF) (Cohen’s effect size: –0.54 large)
Environmental QoL 18.20 (4.38) 18.40 (1.82) NS (U = 150.50 (Z = –1.372), p = 0.170)
(WHOQOL-BREF)
Anxiety (HADS) 6.50 (3.65) 2.55 (1.64) U = 65.50 (Z = –3.665), p < 0.001;
(Cohen’s effect size: –0.58 large)
Depression (HADS) 3.75 (3.43) 1.30 (1.42) U = 106.50 (Z = –2.582), p = 0.010;
(Cohen’s effect size: –0.41 medium)
Neuroticism (BFI) 22.95 (6.60) 15.50 (4.84) U = 74.00 (Z = –3.415), p < 0.001;
(Cohen’s effect size: –0.54 large)
Stress (PSS) 14.00 (7.62) 6.95 (4.32) U = 90.00 (Z = –2.982), p = 0.003;
(Cohen’s effect size: –0.47 medium)
Metacognition (MCQ-30) 59.30 (5.90) 34.20 (2.53) U = 0.00 (Z = –5.421), p < 0.001
(Cohen’s effect size: –0.86 large)
NS, not significant.
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(r (38) = 0.417, p = 0.007), however the association
between CCI-S scores and neuroticism was no longer
significant when age, years in education, and gender
were also controlled for (r (38) = 0.291, p = 0.069).
The association between CCI-S scores and anxiety
remained non-significant when controlling for age,
gender, and years in education, as well as metacog-
nition (r (38) = 0.218, p = 0.176).
Ad-hoc analysis
Ad-hoc analyses were run to build on the ini-
tial main aims of this research and gain further
insight into the initial research findings and potential
profiles of SCD. Thus, due to past research regard-
ing the association between metacognition, anxiety
and depression (e.g., [31]), and the findings from
the present study’s initial analysis, it was decided
that additional group-difference analyses would be
run on all variables employing metacognition as the
grouping variable. Participants with the highest 20
scores and the lowest 20 scores on the MCQ-30 were
grouped and analyzed across all study variables. The
rounded threshold of 20 participants was selected so
that the overall size of the two groups was of similar
size to the study’s SCD group (N = 44) while ensur-
ing the MCQ-30 scores were distinct. Table 4 shows
the means and standard deviations for each variable
and whether significant group differences were iden-
tified. Those with higher scores of metacognition,
thus metacognitive dysfunction, were significantly
more likely to experience poor scores on SCD, anx-
iety, depression, stress, neuroticism, psychological
and social QoL.
DISCUSSION
The aim of the current study was to further char-
acterize SCD (in the general public) with respect
to general objectively measured cognitive function-
ing, anxiety, depression, QoL, stress, metacognition,
and neuroticism. The results of the analysis indicate
that there are significant differences between those
older adults who are experiencing SCD compared to
those who are not. Specifically, individuals with SCD
experienced higher levels of anxiety, depression, and
stress; displayed poorer scores on psychological and
environmental QoL; poorer levels of metacognitive
dysfunction; and were more likely to be neurotic.
In the SCD group, all these variables were also
found to be significantly correlated with CCI-S
scores therefore indicating a possible relationship
with the participants subjective changes in cognition.
Interestingly, irrespective of the significant between-
group differences, stress, metacognition, anxiety, and
depression were also significantly correlated with
CCI-S scores in the non-SCD group. This result could
be explained by the fact that not all those experiencing
difficulties with negative affective symptoms, stress,
and metacognitive dysfunction, are at a greater risk
of experience SCD. The results of the partial corre-
lation analysis suggest that anxiety, depression, and
metacognition are inter-correlated, thus they seem
to all be related to one another. Intercorrelation is
assumed due to both the pattern of statistical findings
(i.e., the impact on scores when controlling for each
variable) and past research [30]. Such a presump-
tion provides strength to the theory that particular
profiles of individuals are more at risk of experi-
encing SCD than others. It must be noted, however,
that the average scores for anxiety and depression
were all within the ‘normal’ range, therefore the
negative affective symptoms being experienced are
sub-clinical. Therefore, it is proposed that their nega-
tive affective symptoms do not have to be identifiable
at a clinical level to potentially have an impact on
one’s health, wellbeing, and cognitive functioning.
There has been much debate over the years regard-
ing whether negative affective symptoms for example
should be identified as a cause or consequence of
cognitive changes, however, causality is very diffi-
cult to determine. SCD is etiologically heterogeneous
and found to be related to for instance normal aging
[2], depression [25, 26], anxiety [13], chronic fatigue
[44], schizophrenia [45], and bipolar disorder [46].
Irrespective of directional causation, changes to
cognitive functioning, whether that be subjectively
or objectively recognized, can still be both a personal
concern as well as a public health concern [47], and
can detrimentally influence QoL and self-perceived
health [8, 9], cause emotional distress and poor well-
being [9], and fear of significant underlying brain
pathology and impending dementia [7, 2]. To identify
cause and effect was not possible in this study, and
therefore we are unable to propose that for instance
SCD is caused by anxiety, depression, stress, neuroti-
cism, and metacognitive dysfunction.
The consistent strength and pattern of statistical fi-
ndings in the core analysis of this study, particularly
the significant group-differences, suggest that there
are distinct profiles of individuals experiencing
SCD in comparison to those who are not. Such
profiles could be explained by the impact of metacog-
nitive dysfunction thus, poor cognitive control at a
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meta-level is likely to have an impact on for instance
negative affective symptoms. Therefore, ad hoc anal-
yses were run using metacognition as the grouping
variable. The metacognitive based group differences
were distinct and indicated certain profiles of individ-
uals. Thus, the group of individuals with higher scores
of metacognition, indicating metacognitive dysfunc-
tion, were significantly more anxious, depressed, str-
essed, neurotic, experiencing poor psychological and
social QoL. Importantly, they were also experiencing
significantly poorer scores on SCD. Consequently,
this suggests that those experiencing metacognitive
dysfunction may not only be more likely to identify
SCD, but also more likely to worry about it and allow
it to impact on their lives to a greater extent than
those with superior metacognitive control. As previ-
ously noted, the relationship between metacognition,
anxiety, and depression are likely inter-correlated and
therefore all impact on one another. Also, it must
be noted that the present study measures metacog-
nitive beliefs, monitoring, and judgements, not how
accurate the participants are at assessing their own
cognitive ability.
Past research suggests that an individual’s knowl-
edge, understanding, and beliefs of their own memory
and cognitive functioning could impact on SCD [31].
Shimamura (2000) postulates that metacognition is
the control and evaluation of cognitive functioning.
It can be argued that the self-evaluation of SCD can be
considered a form of metacognitive monitoring [32].
For example, an individual may evaluate their mem-
ory by making a judgement regarding something they
have learned. Shimamura (2000) proposed that such
monitoring is likely to therefore influence metacog-
nitive control. For instance, in the above judgement
on learning, the individual may evaluate that they did
not learn something very well and therefore would
allocate more time to learning it again.
Zanardo et al. (2006) put forward the idea that
metacognition is multidimensional, thus based on
memory monitoring; memory attributional style; fac-
tual knowledge of how the memory functions and
knowledge of memory strategies; memory related
self-efficacy beliefs; and memory related influences
such as the impact of depression and anxiety [31].
These dimensions provide a possible explanation for
the initial and ad hoc findings within this study. For
instance, in relation to the dimension of memory
related self-efficacy beliefs, thus memory ability, self-
assessment, and feelings towards changes to memory.
The evaluation of one’s memory and self-efficacy
beliefs are believed to be related to age; hence older
adults were perceived to be more pessimistic about
their memory ability [48]. Zanardo et al. (2006) sug-
gested that a self-fulfilling prophecy is the reason
why some older adults have a negative perception and
poorer level of self-efficacy of their memory ability.
Thus, they propose some older adults perceive their
memory ability based on what other people think of
them [31].
Arguably, such a metacognitive theoretical per-
spective should be considered in the translation from
research into clinical practice. Such a perspective
encapsulates the findings from both the initial and
ad hoc analyses in the present study. For instance,
poor perception of cognitive ability seems to be the
result of a more global metacognitive process involv-
ing the influence of many variables such as mood,
anxiety, QoL, self-efficacy, neuroticism, stress, and
metacognitive monitoring. The complex interplay of
multiple variables such as these will likely impact
on general health. For example, higher levels of self-
efficacy are related to more engagement in behaviors
that are regarded as healthy (i.e., keeping physically
and mentally fit) [49]. Poor health-related behav-
ior is related to low mood, higher levels of anxiety,
and cognitive decline [50]. From a clinical and int-
ervention perspective, Zanardo et al. (2006) pro-
posed that improving older adults’ self-efficacy and
attributional style of their cognitive functioning is
possible by encouraging them to have more confi-
dence in their cognitive capabilities and their ability
to accurately judge their cognition [31]. Furthermore,
such improvements could encourage individuals to
engage more in health-related behaviors, and ulti-
mately improve SCD, metacognitive functioning,
mood, anxiety, stress, etc.
Such theoretical and research evidence provides a
possible explanation for the initial and ad hoc res-
ults found in this study. Thus, those in the current
study with SCD also had higher levels of anxiety,
depression, stress, neuroticism, and poor physical and
psychological QoL. Consequently, we hypothesize
that symptoms of SCD may be contributed to by a
combination of excessive rumination, worry, and neg-
ative bias towards threats (i.e., cognitive decline). The
results from the ad hoc analyses also suggest pro-
file differences possibly characterized by levels of
metacognition.
Study limitations and future research
A potential limitation of this study is its cross-
sectional design. In relation to all variables measured,
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this study was the first testing phase in a planned
longitudinal study. Most of the sample agreed to be
contacted again in the future to be re-tested in order
to identify any possible changes over time. Impor-
tantly, past research has identified that psychosocial
stress for instance was significantly more prevalent
in the SCD group compared to those with MCI or
dementia [29]. Participants were tested again after
three-years and they found that in the SCD group,
only 14% reported the presence of psychosocial stress
compared to 71% at baseline therefore highlighting
the changeable nature of stress and the impact it can
have. Findings such as this not only support the need
for a longitudinal study to re-test the participants, but
also the need for variables such as metacognition to
be measured at baseline and follow-up in clinical and
research settings, and that cognition should not be
tested and appraised in isolation. Consequently, this
could give rise to future research into causality, thus
intervention-based studies on metacognitive therapy
and SCD. An additional study limitation is the lack of
established causal links between the variables. Fur-
ther research would need to be carried out to identify
such links.
To conclude, in response to the research, theoreti-
cal associations, and effective intervention evidence,
it is plausible to suggest that metacognition and neg-
ative affective symptoms play an important role in
the characterization of SCD. Furthermore, having a
better understanding of SCD characteristics could
inform clinical interventions to improve symptoms of
SCD. This study is a valuable contribution to research
regarding the characterization of SCD profiles in
the general population. The sample reported poorer
scores in relation to metacognitive dysfunction, neg-
ative affective symptoms, stress, psychological and
environmental QoL, but not social and physical QoL.
Therefore, regardless of whether the SCD is the
cause or consequence of such distress, their cogni-
tive changes and concerns should not be dismissed
as benign. Suitable SCD monitoring could enable
potentially reversible indications to be treated (e.g.,
metacognitive dysfunction), thus not only with the
aim to alleviate symptoms of SCD but also to reduce
further risk of cognitive decline [21].
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